Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-03-2019 | Letter to the Editor

Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy

Authors: Eric Guedj, Thomas Graillon, Olivier Chinot, David Taieb

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2019

Excerpt

Sir, …

Galldiks N, Albert NL, Sommerauer M, Grosu AL, Ganswindt U, Law I, et al. PET imaging in patients with meningioma-report of the RANO/PET group. Neuro Oncol. 2017;19:1576–87. https://doi.org/10.1093/neuonc/nox112.CrossRefPubMedPubMedCentral

Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, et al. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016;17:e383–91. https://doi.org/10.1016/S1470-2045(16)30321-7.CrossRefPubMed

Kaley T, Barani I, Chamberlain M, McDermott M, Panageas K, Raizer J, et al. Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro Oncol. 2014;16:829–40. https://doi.org/10.1093/neuonc/not330.CrossRefPubMedPubMedCentral

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35. https://doi.org/10.1056/NEJMoa1607427.CrossRefPubMedPubMedCentral

Graillon T, Romano D, Defilles C, Saveanu A, Mohamed A, Figarella-Branger D, et al. Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review. J Neurosurg. 2017;127:660–9. https://doi.org/10.3171/2016.8.JNS16995.CrossRefPubMed

Soto-Montenegro ML, Peña-Zalbidea S, Mateos-Pérez JM, Oteo M, Romero E, Morcillo M, et al. Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice. PLoS One. 2014;9:e111624. https://doi.org/10.1371/journal.pone.0111624.CrossRefPubMedPubMedCentral

Sommerauer M, Burkhardt JK, Frontzek K, Rushing E, Buck A, Krayenbuehl N, et al. 68Gallium-DOTATATE PET in meningioma: a reliable predictor of tumor growth rate? Neuro Oncol. 2016;18:1021–7. https://doi.org/10.1093/neuonc/now001.CrossRefPubMedPubMedCentral

Gerster-Gilliéron K, Forrer F, Maecke H, Mueller-Brand J, Merlo A, Cordier D. 90Y-DOTATOC as a therapeutic option for complex recurrent or progressive meningiomas. J Nucl Med. 2015;56:1748–51. https://doi.org/10.2967/jnumed.115.155853.CrossRefPubMed

Marincek N, Radojewski P, Dumont RA, Brunner P, Müller-Brand J, Maecke HR, et al. Somatostatin receptor-targeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial. J Nucl Med. 2015;56:171–6. https://doi.org/10.2967/jnumed.114.147256.CrossRefPubMed

10.

Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E, et al. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging. 2009;36:1407–16. https://doi.org/10.1007/s00259-009-1115-z.CrossRefPubMed

11.

Sabet A, Ahmadzadehfar H, Herrlinger U, Wilinek W, Biersack HJ, Ezziddin S. Successful radiopeptide targeting of metastatic anaplastic meningioma: case report. Radiat Oncol. 2011;6:94. https://doi.org/10.1186/1748-717X-6-94.CrossRefPubMedPubMedCentral

12.

Seystahl K, Stoecklein V, Schüller U, Rushing E, Nicolas G, Schäfer N, et al. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. Neuro Oncol. 2016;18:1538–47. https://doi.org/10.1093/neuonc/now060.CrossRefPubMedPubMedCentral

13.

van Essen M, Krenning EP, Kooij PP, Bakker WH, Feelders RA, de Herder WW, et al. Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med. 2006;47:1599–606.PubMed

14.

Kreissl MC, Hänscheid H, Löhr M, Verburg FA, Schiller M, Lassmann M, et al. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiat Oncol. 2012;7:99. https://doi.org/10.1186/1748-717X-7-99.CrossRefPubMedPubMedCentral

15.

Backhaus P, Huss S, Kösek V, Weckesser M, Rahbar K. Lung metastases of intracranial atypical meningioma diagnosed on post therapeutic imaging after 177Lu-DOTATATE therapy. Clin Nucl Med. 2018;43:e184–5. https://doi.org/10.1097/RLU.0000000000002077.CrossRefPubMed

16.

Cremonesi M, Ferrari ME, Bodei L, Chiesa C, Sarnelli A, Garibaldi C, et al. Correlation of dose with toxicity and tumour response to 90Y- and 177Lu-PRRT provides the basis for optimization through individualized treatment planning. Eur J Nucl Med Mol Imaging. 2018;45:2426–41. https://doi.org/10.1007/s00259-018-4044-x.CrossRefPubMed

17.

Sandström M, Garske-Román U, Granberg D, Johansson S, Widström C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54:33–41. https://doi.org/10.2967/jnumed.112.107524.CrossRefPubMed

18.

Sundlöv A, Sjögreen-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, et al. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017;44:1480–9. https://doi.org/10.1007/s00259-017-3678-4.CrossRefPubMedPubMedCentral

19.

Del Prete M, Buteau FA, Beauregard JM. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: a simulation study. Eur J Nucl Med Mol Imaging. 2017;44:1490–500. https://doi.org/10.1007/s00259-017-3688-2.CrossRefPubMed

Title: Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy
Authors: Eric Guedj
Thomas Graillon
Olivier Chinot
David Taieb
Publication date: 01-03-2019
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2019
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-018-4221-y

At a glance: The STEP trials

Springer Medicine

Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2019

Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial

Ectopic corticotropin-releasing hormone syndrome caused by pancreatic neuroendocrine tumor localized by 68Ga-DOTATATE PET/CT

Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation

Salvage peptide receptor radionuclide therapy with [177Lu-DOTA,Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours

Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors

18F-DOPA PET/CT in brain tumors: impact on multidisciplinary brain tumor board decisions